Related Experiment Videos
Human immunodeficiency virus type I as a target for gene therapy
1Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA. gottf003@mc.duke.edu
Frontiers in Bioscience : a Journal and Virtual Library
|December 5, 1997
Summary
Gene therapy offers promising strategies to inhibit human immunodeficiency virus type 1 (HIV-1) replication by targeting viral genes and products. While successful in cell cultures, clinical applications for HIV-1 gene therapy are still in early development.
Area of Science:
- Virology
- Gene Therapy
- Molecular Biology
Background:
- The human immunodeficiency virus type 1 (HIV-1) life cycle involves complex interactions with host cells.
- Understanding viral gene products is crucial for developing targeted therapeutic interventions.
- Gene therapy presents a novel approach to combat HIV-1 infection.
Purpose of the Study:
- To review the HIV-1 life cycle, focusing on viral gene product functions.
- To summarize gene therapy strategies targeting HIV-1 genes and products.
- To assess the potential of gene therapy in inhibiting HIV-1 replication.
Main Methods:
- Review of existing literature on HIV-1 life cycle and gene products.
- Analysis of gene therapy approaches targeting specific viral components.
- Evaluation of studies demonstrating inhibition of HIV-1 replication in vitro.
Main Results:
- Numerous stages and gene products of the HIV-1 life cycle are viable targets for gene therapy.
- Gene therapy interventions have shown success in suppressing HIV-1 replication in laboratory settings.
- Clinical trials for HIV-1 gene therapy are in their nascent stages.
Conclusions:
- Targeting HIV-1 genes and products via gene therapy is a viable strategy for antiviral treatment.
- Further research and clinical development are necessary to translate in vitro success to patient care.
- Gene therapy holds potential for future HIV-1 management, pending clinical validation.